Kroger launches Pearl Street Academy
New development platform brings together leadership training across entire enterprise, offering growth opportunities for associates.
New development platform brings together leadership training across entire enterprise, offering growth opportunities for associates.
In the interim, president and chief executive officer Kirk Tanner, chief customer officer Tiffany Menyhart, and chief commercial officer Nate Champagne will jointly oversee the company’s U.S. business.
This latest cohort reflects growing investment in data-driven decision-making, regulatory intelligence, and next-generation product development across the nutrition and health space.
Electrolit launches 12-oz Strawberry Kiwi six-pack, now at Kroger, H-E-B, and Publix.
Better Care Services platform connects customers to virtual care and nutrition support, complementing fast, convenient access to medications through Walmart’s nationwide pharmacy network.
Infographic and white paper emphasize mobility as a balanced system beyond joint health alone—and the Everwell Health ingredients that help keep life in motion.
New launches emphasize Camber’s continued investment in expanding patient access to high-quality, affordable treatments.
Messi joins the Duracell scientist to prove that Power Boost ingredients are the difference maker.
Expands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight Loss.
Lovelady will continue in her role as founder and CEO of Each & Every, the clean personal care brand she launched in 2018.
Gives plan sponsors much greater pricing visibility and transparency by shifting infusion therapies covered under the medical benefits to the pharmacy benefit.
Consumers are simultaneously trading down for everyday moments and trading up for premium, health-led experiences.
Aurigene provides AI-enabled integrated drug discovery services supporting Alveus’ research programs in obesity and metabolic disease.
‘Customers and patients will continue to have the same great experience.’
Albertsons’ Q4 results showed continued pressure on its pharmacy, with a $773.8 million opioid-related charge causing a net loss and highlighting reimbursement and pricing issues.
Strong year-over-year sales growth that was driven by core pharmacy prescription growth and sale of GLP-1 drugs.